Gain Therapeutics appoints Matthias Alder as COO effective Oct 15, 2021

Gain Therapeutics, Inc.

Annual base salary of $400,000; eligible for 35% incentive target under management plan.
Receives option grant of 200,000 shares with standard vesting and 200,000 RSUs tied to business/clinical milestones.
Alder joins from Autolus Therapeutics where he was Chief Business Officer; previously EVP at Sucampo Pharmaceuticals.
Appointment supports preparation for lead program in Gaucher and Parkinson's to enter clinical trials in 2022.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthias Alder

Chief Operating Officer

GANX · Gain Therapeutics, Inc.

Effective: 2021-10-15
Filed: October 20, 2021, 7:59 PM ET

On October 19, 2021, Gain Therapeutics, Inc. (the “Company”) publicly announced the appointment of Matthias Alder, age 56, to serve as the Company’s Chief Operating Officer effective as of October 15, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthias Alder was appointed as Chief Operating Officer at Gain Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On October 19, 2021, Gain Therapeutics, Inc. (the “Company”) publicly announced the appointment of Matthias Alder, age 56, to serve as the Company’s Chief Operating Officer effective as of October 15, 2021.

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-21-013308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.